| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | 1 | Y | 0 Induction SST | 1273 | 935 | 117 | 64 | 34 | 15 | 4 | 09/24/2018 | 329 | 138 |
| 935 | 117 | 64 | 34 | 15 | 4 | |||||||||
| 2 | Y | 1 Standard Systemic Therapy Only | 337 | 49 | 21 | 14 | 3 | 0 | 09/24/2018 | |||||
| 2 SST + Surgery/RT | 330 | 41 | 15 | 9 | 3 | 0 | ||||||||
| 667 | 90 | 36 | 23 | 6 | 0 | |||||||||
| S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | 1 | Y | 0 Pre-Rand. SST | 332 | 194 | 49 | 23 | 13 | 4 | 2 | 03/08/2021 | 262 | 96 | |
| 194 | 49 | 23 | 13 | 4 | 2 | |||||||||
| 2 | Y | 1 Systemic Immuno. Only | 65 | 13 | 8 | 5 | 1 | 1 | 03/08/2021 | |||||
| 2 Nephrectomy + Systemic Immuno. | 64 | 20 | 9 | 3 | 0 | 0 | ||||||||
| 129 | 33 | 17 | 8 | 1 | 1 | |||||||||
| S1937-Blad, Mets, Eribulin + Gem vs SOC | 1 | Y | 1 Physician Choice Chemo | 184 | 42 | 26 | 12 | 5 | 1 | 0 | 06/28/2021 | 243 | 75 | |
| 2 Eribulin | 8 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 3 Eribulin + Gemcitabine | 41 | 28 | 14 | 4 | 1 | 0 | ||||||||
| 91 | 54 | 26 | 9 | 2 | 0 | |||||||||
| S2200-pRCC, Adv, Cabo ± Atezo | 1 | Y | 1 Cabozantinib Only | 200 | 17 | 6 | 2 | 1 | 0 | 0 | 03/24/2023 | 187 | 75 | |
| 2 Cabozantinib + Atezolizumab | 17 | 7 | 3 | 2 | 2 | 0 | ||||||||
| 34 | 13 | 5 | 3 | 2 | 0 | |||||||||
| S2210-Pros, High Risk, BRCA, Neoadj Carbo | 1 | Y | 1 Carboplatin + Surgery | 44 | 5 | 4 | 2 | 1 | 0 | 0 | 03/01/2024 | 144 | 40 | |
| 5 | 4 | 2 | 1 | 0 | 0 | |||||||||
| S2312-Pros, MCRPC, Cab +/- Carb | 1 | Y | 0 Signed informed consent | 500 | 31 | 31 | 23 | 11 | 3 | 0 | 11/27/2024 | 248 | 82 | |
| 31 | 31 | 23 | 11 | 3 | 0 | |||||||||
| 2 | Y | 1 Cabazitaxel + Prednisone | 11 | 11 | 10 | 4 | 1 | 0 | 11/27/2024 | |||||
| 2 Cabazitaxel + Carboplatin + Prednisone | 12 | 12 | 11 | 2 | 2 | 0 | ||||||||
| 23 | 23 | 21 | 6 | 3 | 0 | |||||||||
| Yes | A031702-GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) | 1 | E | Total Registrations | 27 | 1 | 0 | 0 | 0 | 0 | 08/09/2019 | 242 | 88 | |
| 27 | 1 | 0 | 0 | 0 | 0 | |||||||||
| A031803-Blad, NMIBC, Gemcitabine + MK-3475 | 1 | E | Total Registrations | 47 | 4 | 0 | 0 | 0 | 0 | 03/18/2020 | 156 | 56 | ||
| 47 | 4 | 0 | 0 | 0 | 0 | |||||||||
| A032103-Urothelial, All Stg, MRD-Based Adj Tx | 0 | E | Total Registrations | 30 | 28 | 22 | 7 | 2 | 0 | 03/19/2024 | 345 | 140 | ||
| 30 | 28 | 22 | 7 | 2 | 0 | |||||||||
| 1 | E | Total Registrations | 21 | 20 | 18 | 10 | 2 | 0 | 03/19/2024 | |||||
| 21 | 20 | 18 | 10 | 2 | 0 | |||||||||
| 2 | E | Total Registrations | 2 | 2 | 2 | 2 | 0 | 0 | 03/19/2024 | |||||
| 2 | 2 | 2 | 2 | 0 | 0 | |||||||||
| NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide | 1 | E | Total Registrations | 14 | 1 | 0 | 0 | 0 | 0 | 09/25/2020 | 273 | 93 | ||
| 14 | 1 | 0 | 0 | 0 | 0 | |||||||||
| NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx | 1 | E | Total Registrations | 18 | 9 | 6 | 2 | 1 | 0 | 03/29/2023 | 273 | 91 | ||
| 18 | 9 | 6 | 2 | 1 | 0 | |||||||||
| NRGGU012-Renal, Stg IV, Stereo Abl Rad Therapy | 1 | E | Total Registrations | 7 | 4 | 1 | 1 | 0 | 0 | 01/10/2024 | 261 | 83 | ||
| 7 | 4 | 1 | 1 | 0 | 0 | |||||||||
| No | A031701-Bladder, ddGC for MIBC with DDR Tumor Alt | 1 | E | Total Registrations | 24 | 1 | 1 | 1 | 1 | 0 | 12/17/2018 | 177 | 55 | |
| 24 | 1 | 1 | 1 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 20 | 3 | 0 | 0 | 0 | 0 | 12/17/2018 | |||||
| 20 | 3 | 0 | 0 | 0 | 0 | |||||||||
| 3 | E | Total Registrations | 3 | 1 | 1 | 0 | 0 | 0 | 12/17/2018 | |||||
| 3 | 1 | 1 | 0 | 0 | 0 | |||||||||
| A031801-GU, mRCC, Cabozantinib ± Radium-223 | 1 | E | Total Registrations | 15 | 0 | 0 | 0 | 0 | 0 | 11/06/2020 | 109 | 39 | ||
| 15 | 0 | 0 | 0 | 0 | 0 | |||||||||
| EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT | 1 | E | Total Registrations | 19 | 6 | 6 | 4 | 1 | 0 | 04/25/2019 | 42 | 16 | ||
| 19 | 6 | 6 | 4 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 1 | 1 | 1 | 1 | 0 | 0 | 04/25/2019 | |||||
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| EA8191-Pros, Local vs Systemic Thrpy | 0 | E | Total Registrations | 65 | 24 | 4 | 0 | 0 | 0 | 09/24/2021 | 193 | 62 | ||
| 65 | 24 | 4 | 0 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 65 | 24 | 4 | 0 | 0 | 0 | 09/24/2021 | |||||
| 65 | 24 | 4 | 0 | 0 | 0 | |||||||||
| EA8192-Blad, High Grade UTUC, Durv + Chemo | 1 | E | Total Registrations | 4 | 1 | 0 | 0 | 0 | 0 | 02/23/2022 | 153 | 53 | ||
| 4 | 1 | 0 | 0 | 0 | 0 | |||||||||
| EA8212-Blad, NMIBC, BRIDGE | 1 | E | Total Registrations | 252 | 125 | 68 | 37 | 10 | 4 | 02/07/2023 | 162 | 73 | ||
| 252 | 125 | 68 | 37 | 10 | 4 | |||||||||
| NRGGU009-Pros, PREDICT-RT | 1 | E | Total Registrations | 94 | 29 | 6 | 3 | 1 | 0 | 03/01/2022 | 466 | 171 | ||
| 94 | 29 | 6 | 3 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 87 | 29 | 6 | 3 | 2 | 0 | 03/01/2022 | |||||
| 87 | 29 | 6 | 3 | 2 | 0 | |||||||||
| NRGGU010-Pros, Parallel De-Intens & Intens Trials | 1 | E | Total Registrations | 68 | 28 | 2 | 1 | 1 | 0 | 01/03/2022 | 451 | 164 | ||
| 68 | 28 | 2 | 1 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 63 | 27 | 2 | 1 | 1 | 0 | 01/03/2022 | |||||
| 63 | 27 | 2 | 1 | 1 | 0 | |||||||||
| NRGGU013-Prostate, High-Risk, Five Fraction Radiation | 1 | E | Total Registrations | 9 | 7 | 4 | 3 | 1 | 0 | 05/28/2024 | 252 | 97 | ||
| 9 | 7 | 4 | 3 | 1 | 0 | |||||||||